Chao Tze-Fan, Liu Chia-Jen, Tuan Ta-Chuan, Liao Jo-Nan, Lin Yenn-Jiang, Chen Tzeng-Ji, Kong Chi-Woon, Chen Shih-Ann
Division of Cardiology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Clinical Medicine, and Cardiovascular Research Center, National Yang-Ming University, Taipei, Taiwan.
Division of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan; Institute of Public Health and School of Medicine, National Yang-Ming University, Taipei, Taiwan.
Can J Cardiol. 2014 Oct;30(10):1196-201. doi: 10.1016/j.cjca.2014.04.010. Epub 2014 Apr 13.
The implantation of a permanent pacemaker (PPM) is life-saving for patients with life-threatening bradycardia. However, the effectiveness and prognosis of PPM implantations for extremely old patients (≥ 90 years old) have not been investigated.
From 2001-2012, a total of 108 patients older than 90 years were identified from 2630 consecutive patients receiving PPM implantations in our hospital as the study group. For each study patient, 4 age-, sex-, and comorbidity-matched subjects who did not have the diagnoses of bradyarrhythmias indicated for PPM implantations were selected from the "Taiwan National Health Research Database" to constitute the control group (n = 432). The study end point was all-cause mortality.
The median age of the study population was 91 (interquartile range, 90-93) years. Among the PPM group, 45 patients died during the follow-up with an annual mortality rate of 18.7%. The risk of mortality did not differ significantly between the study and control groups with a hazard ratio of 1.020 (95% confidence interval, 0.724-1.437; P = 0.912) after the adjustment for age and sex. Procedure-related complications occurred in 7.4% of the patients receiving PPM implants, and pocket hematoma was the most common. The preimplantation history of heart failure and cerebrovascular accident, rather than age, were significant predictors of mortality among PPM recipients.
Nonagenarians with severe bradyarrhythmias could retain the same life expectancies as those without bradyarrhythmias through PPM implantations. Extremely old age (≥90 years) should not be a barrier for PPM implants when indications are present.
植入永久性起搏器(PPM)对有危及生命的心动过缓的患者来说是救命之举。然而,对于极高龄患者(≥90岁)植入PPM的有效性及预后尚未得到研究。
2001年至2012年期间,从我院连续接受PPM植入的2630例患者中,共识别出108例年龄超过90岁的患者作为研究组。对于每例研究患者,从“台湾国民健康研究数据库”中选取4例年龄、性别和合并症相匹配但未诊断出适合植入PPM的缓慢性心律失常的受试者,组成对照组(n = 432)。研究终点为全因死亡率。
研究人群的中位年龄为91岁(四分位间距,90 - 93岁)。在PPM组中,45例患者在随访期间死亡,年死亡率为18.7%。在对年龄和性别进行调整后,研究组和对照组的死亡风险无显著差异,风险比为1.020(95%置信区间,0.724 - 1.437;P = 0.912)。接受PPM植入的患者中有7.4%发生了与手术相关的并发症,其中囊袋血肿最为常见。植入前有心力衰竭和脑血管意外病史,而非年龄,是PPM接受者死亡率的重要预测因素。
患有严重缓慢性心律失常的九旬老人通过植入PPM可保持与无缓慢性心律失常者相同的预期寿命。当有适应证时,极高龄(≥90岁)不应成为植入PPM的障碍。